MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ctr.70370

Медицинская библиотека · Clinical transplantation · 2025

Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial.

Bürker Britta S, Brautaset Englund Kristine V, Myrdal Østby Charlotte, Andersson Stein, Gullestad Lars, Broch Kaspar

Клиническое исследование II фазыКлиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Cognitive dysfunction after successful heart transplantation (HTx) is not uncommon. Lower hemoglobin levels have previously been associated with cognitive dysfunction in heart transplant recipients (HTx recipients). In a randomized, placebo-controlled, double-blind treatment trial, we assessed as a pre-specified secondary outcome whether a single intravenous iron supplement for iron deficiency in HTx recipients resulted in changes in cognitive function after 6 months.

METHODS

In the "Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients" (IronIC) trial, we assessed cognitive function at baseline and at 6-month follow-up with the following tests of the Cambridge Neuropsychological Test Automated Battery: Reaction Time, Paired Associates Learning, and Spatial Working Memory. Of 94 participants with cognitive data at baseline and follow-up, 49 were randomized to the single intravenous iron supplement, while 45 received placebo.

RESULTS

Raw score changes from baseline to follow-up did not differ statistically significantly between study groups (two measures of each test analyzed). In the total sample, 27%-44% of participants performed at baseline at least one standard deviation below the normative mean on measures of memory and working memory/executive functions. Exploratory analyses indicated that performance on measures of memory might decrease more than expected with increasing age.

CONCLUSION

A single intravenous iron supplement for iron deficiency in HTx recipients did not result in statistically significant cognitive changes after 6 months. The group as a whole performed approximately half a standard deviation below the normative mean on measures of memory and working memory/executive functions. Regular cognitive screening after HTx is recommended.

CLINICAL TRIAL REGISTRATION: Trial Registration: ClinicalTrials.gov identifier: NCT03662789.

Для цитирования: Bürker Britta S, Brautaset Englund Kristine V, Myrdal Østby Charlotte, Andersson Stein, Gullestad Lars, Broch Kaspar. Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial.. Clinical transplantation. 2025. DOI: 10.1111/ctr.70370.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.